

**DAFTAR PUSTAKA**

1. A.H. Nwabo Kamdje, P.F. Seke Etet, L. Vecchio, J.M. Muller, M. Krampera, K.E. Lukong Signaling pathways in breast cancer: therapeutic targeting of the microenvironment *Cell Signal*, 26 (12) (2014), pp. 2843-2856
2. Abdulkareem, I. H. and Zurmi, I. B. (2012) ‘Review of hormonal treatment of breast cancer’, *Nigerian Journal of Clinical Practice*, 15(1), pp. 9–14. doi: 10.4103/1119-3077.94088.
3. Aebi S, Davidson T, Gruber G, Castiglione M ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010;21(Suppl 5):v9–v14.
4. Alqaisi A, Chen L, Romond E, et al. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. *Breast Cancer Res Treat*. 2014;148(2):437–444.
5. Anton Oseledchyk, Mary L Gemignani, Qin C Zhou et al. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. *Int J Gynecol Cancer* 2021;31:222–231
6. Appleton, D., Hackney, L., & Narayanan, S. (2014). Ultrasonography alone for diagnosis of breast cancer in women under 40. *The Annals of The Royal College of Surgeons of England*, 96(3), 202–206.

7. Asselin-Labat M-L, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. Control of mammary stem cell function by steroid hormone signalling. *Nature* 2010;465:798–802.
8. B. Huang, Y. Omoto, H. Iwase, et al. Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer *Proc Natl Acad Sci USA*, 111 (5) (2014), pp. 1933-1938
9. B. Lloyd-Lewis, O.B. Harris, C.J. Watson, F.M. Davis Mammary stem cells: premise, properties, and perspectives *Trends Cell Biol*, 27 (8) (2017), pp. 556-567
10. B. Schade, R. Lesurf, V. Sanguin-Gendreau, et al. beta-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression *Cancer Res*, 73 (14) (2013), pp. 4474-4487
11. Bahl M, Baker JA, Kinsey EN, Ghate SV. Architectural distortion on mammography: correlation with pathologic outcomes and predictors of malignancy. *AJR Am J Roentgenol*. 2015;205:1339–45.
12. Blumgart, E. I., Uren, R. F., Nielsen, P. M. F., Nash, M. P., & Reynolds, H. M. (2011). Lymphatic drainage and tumour prevalence in the breast: a statistical analysis of symmetry, gender and node field independence. *Journal of Anatomy*, 218(6), 652–659.
13. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J*

14. Brewer HR, Jones ME, Schoemaker MJ. et al. Family history and risk of breast cancer: an analysis accounting for family structure. *Breast Cancer Res Treat.* 2017;165:193–200.
15. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of clinical oncology clinical practice guideline update on ovarian suppression. *J Clin Oncol* 2016;34:1689–701.
16. C. Pauli, B.D. Hopkins, D. Prandi, et al. Personalized in vitro and in vivo cancer models to guide precision medicine *Cancer Discov*, 7 (5) (2017), pp. 462-477
17. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, Group EGW. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2011;
18. Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). *Breast.* 2018; 39:131–138. doi:10.1016/j.breast.2018.03.002
19. Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C. Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia. *Breast.* 2018;37:163–169
20. Castaneda, S.A. and Strasser, J. Updates in the treatment of breast cancer with radiotherapy. *Surg Oncol Clin N Am.* 2017; 26: 371–382
21. Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American Joint

- Committee on Cancer breast cancer staging system. *Oncologist*. 2017;22(11):1292–300.
22. Cheang MC, Martin M, Nielsen TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*. 2015;20(5):474–482
23. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA*. 2011;306:1884–1890
24. Chlebowski, R. T. and Anderson, G. L. (2012) ‘Changing concepts: Menopausal hormone therapy and breast cancer’, *Journal of the National Cancer Institute*, 104(7), pp. 517–527. doi: 10.1093/jnci/djs014.
25. Cho YJ, Kim ML, Lee SY, Lee HS, Kim JM, Joo KY. Laparoendoscopic single-site surgery (LESS) versus conventional laparoscopic surgery for adnexal preservation: a randomized controlled study. *Int J Womens Health*. 2012;4:85–91.
26. Clèries R, Rooney RM, Vilardell M, Espinàs JA, Dyba T, Borràs JM. Assessing predicted age-specific breast cancer mortality rates in 27 European countries by 2020. *Clin Transl Oncol*. 2018;20(3):313–321.
27. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and \ *Lancet*. 2014;384(9938):164-172.
28. Darlington, A. J. (2015). *Anatomy of the Breast. Digital Mammography*, 3–10. doi:10.1007/978-3-319-04831-4\_1
29. Demeestere I, Brice P, Peccatori FA et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and

- fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. *J Clin Oncol* 2016; 34: 2568–2574
30. Earl HM, Hiller L, Vallier A-L, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. *J Clin Oncol*. 2018;36
  31. Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary staging of breast cancer: what the radiologist should know. *RadioGraphics*. 2013;33:1589–612..
  32. Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. *Obstet Gynecol* 2015; 126: 187–195.
  33. Elgindy EA, El-Haieg DO, Khorshid OM et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. *Obstet Gynecol* 2013; 121: 78–86.
  34. Fahlen M, Fornander T, Johansson H. et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. *Eur J Cancer*. 2013;49:52–59.
  35. Feng, Y., dkk (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & Diseases* (2018)
  36. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLAVIJOCAN 2012 v1.1. Cancer Incidence and Mortality Worldwide France

- International Agency for Research on Cancer, 2014. Available from: <http://globocan.iarc.fr>.
37. Fost C, Duwe F, Hellriegel M, Schweyer S, Emons G, Grundker C. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. *Oncol Rep* (2011) 25(5):1481–7.10.3892/or.2011.1188
  38. Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018). Molecular Subtypes and Local-Regional Control of Breast Cancer. *Surgical Oncology Clinics of North America*, 27(1), 95–120. Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. *BMC Cancer*. 2016;16(1):734.
  39. Francis PA, Pagani O, Fleming GF, et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *N Engl J Med*. 2018;379(2):122-137
  40. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2015;372: 436-446
  41. Funmilola A. Fisusia, and Emmanuel O. Akala. Drug Combinations in Breast Cancer Therapy. *Pharm Nanotechnol*. 2019 Sep; 7(3): 3–23.
  42. Gabriella Ferrandinaa, Giulia Amadioa, Andrea Marcellusi, et al. (2015) Bilateral Salpingo-Oophorectomy vs GnRh Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment. The final

authenticated version is available online at: <http://dx.doi.org/10.1007/s40261-017-0571-7>

43. Ghoncheh M, Mohammadian-Hafshejani A, Salehiniya H. Incidence and Mortality of Breast Cancer and their Relationship to Development in Asia. *Asian Pac J Cancer Prev*. 2015;16(14):6081–6087.
44. Ginsburg, O. et al. The global burden of women's cancers: a grand challenge in global health. *Lancet* 389, 847–860 (2017).
45. Girgert R, Emons G, Grundker C. 17beta-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib. *Oncol Rep* (2017) 37:1212–8.
46. Girgert R, Emons G, Grundker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. *Breast Cancer Res Treat* (2012) 134:199–205.
47. Girgert R, Emons G, Grundker C. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17beta-estradiol. *BMC Cancer* (2014) 14:935. 102.
48. Grundker C, Bauerschmitz G, Schubert A, Emons G. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH. *Int J Oncol* (2016) 48(6):2713–21.
49. Grundker C, Bauerschmitz G, Schubert A, Emons G. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH. *Int J Oncol* (2016) 48(6):2713–21.10.3892/ijo.2016.3491

50. Hagemann AR, Zigelboim I, Odibo AO, Rader JS, Mutch DG, Powell MA. Costbenefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer. *Breast J.* 2011;17: 103-105.
51. Hall, John E., and Arthur C. Guyton. *Guyton and Hall Textbook of Medical Physiology*. 13th Edition. USA : Elsevier, 2016.
52. Haloua MH, Krekel NM, Winters HA, et al. A systematic review of oncoplastic breast-conserving surgery: current weaknesses and future prospects. *Ann Surg* 2013; 257: 609–20.
53. Harbeck, Nadia, et al. “Breast Cancer.” *Nature Reviews Disease Primers*, vol. 5, no. 1, 2019, doi:10.1038/s41572-019-0111-2.
54. Harbeck, Nadia, et al. “Breast Cancer.” *Nature Reviews Disease Primers*, vol. 5, no. 1, 2019, doi:10.1038/s41572-019-0111-2.
55. Heemskerkgerritsen B A M, Seynaeve C, Asperen C J V, et al. Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction[J]. *J Natl Cancer Inst*, 2015, 107(9).
56. Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. *BMC Cancer*. 2016;16(1):734
57. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al; ABREAST Investigators. The global breast cancer burden: variations in epidemiology and survival. *Clin Breast Cancer*. 2005;6(5):391–401.
58. Huerta-Reyes, M., Maya-Núñez, G., Pérez-Solis, M. A., López-Muñoz, E., Guillén, N., Olivo-Marin, J.-C., & Aguilar-Rojas, A. (2019). Treatment of Breast



- Cancer With Gonadotropin-Releasing Hormone Analogs. *Frontiers in Oncology*, 9. doi:10.3389/fonc.2019.00943
59. Humphrey KL, Saksena MA, Freer PE, Smith BL, Rafferty EA. To do or not to do: axillary nodal evaluation after ACOSOG Z0011 trial. *Radiographics*. 2014;34:1807–1816
60. Huzarski T, Byrski T, Gronwald J, et al. Ten year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. *J Clin Oncol*. 2013;31(26):3191-3196.
61. J.E. Visvader, J. Stingl Mammary stem cells and the differentiation hierarchy: current status and perspectives *Genes Dev*, 28 (11) (2014), pp. 1143-1158
62. J.L. Inman, C. Robertson, J.D. Mott, M.J. Bissell Mammary gland development: cell fate specification, stem cells and the microenvironment *Development*, 142 (6) (2015), pp. 1028-1042
63. J.L. Warren, K.R. Yabroff Challenges and opportunities in measuring cancer recurrence in the United States *JNCI: Journal of the National Cancer Institute*, 107 (8) (2015)
64. J.M. Renoir, V. Marsaud, G. Lazennec Estrogen receptor signaling as a target for novel breast cancer therapeutics *Biochem Pharmacol*, 85 (4) (2013), pp. 449-465
65. Jesinger, R. A. (2014). Breast Anatomy for the Interventionalist. *Techniques in Vascular and Interventional Radiology*, 17(1), 3–9. doi:10.1053/j.tvir.2013.12.002
66. Jiayu Wang, Binghe Xu, Peng Yuan, et al., Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally

- Advanced or Metastatic Breast Cancer. *Medicine (Baltimore)*. 2015 Jul; 94(26): e1006
67. Jiyoung Kim, Minkook Kim, Jun Ho Lee, et al, Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy? *The Breast* Volume 23, Issue 5, October 2014, Pages 670-675
68. Joseph A. Sparano, Robert J. Gray, Della F. Makower, et al. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. *JAMA Oncol.* 2020;6(3):367-374
69. K. Yang, X. Wang, H. Zhang, et al. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies *Lab Invest*, 96 (2) (2016), pp. 116-136
70. Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain? *Clin Cancer Res.* 2018;24(8):1795-1804. doi:10.1158/1078-0432.CCR-17-3351
71. Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P., & Starosławska, E. (2015). Breast cancer risk factors. *Menopausal Review*, 3, 196–202.
72. Kaprara A, Huhtaniemi IT. The hypothalamus–pituitary–gonad axis: tales of mice and men. *Metabolism.* (2018) 86:3–17. 10.1016/j.metabol.2017.11.018
73. Kelly Metcalfe, Henry T. Lynch, et al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *JAMA Oncol.* 2015;1(3):306-313.

74. Kispert S, McHowat J. Recent insights into cigarette smoking as a lifestyle risk factor for breast cancer. *Breast Cancer: Targets and Therapy*. 2017;9:127–132
75. Koo, M. M., von Wagner, C., Abel, G. A., McPhail, S., Rubin, G. P., & Lyrtzopoulos, G. (2017). Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis. *Cancer Epidemiology*, 48, 140–146.
76. Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.[J]. *J Natl Cancer Inst*, 2017, 109(1):djw177.
77. Kounq Jin Suh, Se Hyun Kim, Kyung-Hun Lee, et al. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. *Cancer Res Treat*. 2017 Oct; 49(4): 1153–1163.
78. Kuhl, C. K. (2015). The Changing World of Breast Cancer. *Investigative Radiology*, 50(9), 615–628.
79. Kul S, Cansu A, Alhan E, Dinc H, Gunes G, Reis A. Contribution of diffusion-weighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors. *AJR Am J Roentgenol*. 2011;196:210–
80. Kwon JS, Pansegrau G, Nourmoussavi M, Hammond G, Carey MS. Long-term consequences of ovarian ablation for premenopausal breast cancer. *Breast Cancer Res Treat*. 2016;157: 565-573.

81. L.P. Hemachandra, H. Patel, R.E. Chandrasena, J. Choi, S.C. Piyankarage, S.Wang, et al., SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites, *Cancer Prev. Res. (Phila.)* 7 (2014) 505–515.
82. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ, editors. WHO Classification of Tumours of the Breast. Fourth ed. IARC; Lyon: 2012. ISBN.13
83. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Jr, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. *BMC Med.* 2016;14:1. 10.1186/s12916-015-0545-7
84. Laura Ciria-Suarez, Paula Jimenez-Fonseca, Raquel Hernández. et al. Estimation of Risk of Recurrence and Toxicity Among Oncologists and Patients With Resected Breast Cancer: A Quantitative Study. *Front. Psychol.* (2020) 11:540083
85. Lee EJ, Han SH, Kang BJ, Kim SH. Imaging and pathologic characterization of the skin thickening or enhancement under the breast MRI. *Investig Magn Reson Imaging.* 2016;20:9–26.
86. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 2011;121:2750–2767.
87. Leonard R. C. F., D. J. A. Adamson, G. Bertelli, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. *Annals of Oncology* (2017) 28: 1811–1816

88. Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, et al. MRI features of inflammatory breast cancer. *AJR Am J Roentgenol.* 2011;197:W769–W776.
89. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review[J]. *Clinical Cancer Research An Official Journal of the American Association for Cancer Research*, 2016, 22(15):3971.
90. Li Z, Hu P, Tu J, Yu N. Luminal B breast cancer : patterns of recurrence and clinical outcome. *Oncotarget.* 2016;7(40):1–10.
91. Liu J-Y, Chen T-J, Hwang S-J. The Risk of Breast Cancer in Women Using Menopausal Hormone Replacement Therapy in Taiwan. *International journal of environmental research and public health.* 2016;13:482
92. Løberg, M., Lousdal, M. L., Bretthauer, M., & Kalager, M. (2015). Benefits and harms of mammography screening. *Breast Cancer Research*, 17(1).
93. Lteif, A., & Javed, A. (2013). Development of the Human Breast. *Seminars in Plastic Surgery*, 27(01), 005–012.
94. M.A. Velasco-Velazquez, N. Homsí, M. De La Fuente, R.G. Pestell, Breastcancer stem cells, *Int. J. Biochem. Cell Biol.* 44 (2012) 573–577.
95. Mădălina Drăgănescu, and Codruăa Carmocan. Hormone Therapy in Breast Cancer. *Chirurgia* (2017) 112: 413-417
96. Makarem N, Chandran U, Bandera EV. et al. Dietary fat in breast cancer survival. *Annu Rev Nutr.* 2013;33:319–348.

97. Makki, J. (2015). Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*, 8, CPath.S31563. doi:10.4137/cpath.s31563
98. Marieb, Elaine N., and Katja Hoehn. *Human Anatomy and Physiology* 9th Edition. San Francisco: Pearson Benjamin Cummings, 2013.
99. Martin M, Holmes FA, Ejlertsen B, et al; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2017;18(12):1688-1700
100. Mazari, F. A. K., Sharma, N., Reid, D., & Horgan, K. (2018). The need for triple assessment and predictors for diagnosis of breast cancer in patients <40 years of age. *Clinical Radiology*, 73(8), 758.e19–758.e25.
101. Metcalfe K, Lynch HT, Foulkes WD, et al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *JAMA Oncol*. 2015;1(3):306–313.
102. Mitra S, Dey P. Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature. *CytoJournal* 2016;13:18
103. Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, et al. A staging system for breast cancer patients that reflects the prognostic significance of underlying tumor biology. *Ann Surg Oncol*. 2017;24(12):3502–9.

104. Modiramani O., N. Najafizadehgan, F. Elahi. Combination of GnRH analogue and aromatase inhibitor as an adjuvant therapy in premenopausal nonmetastatic breast cancer. *Journal of Clinical Oncology* 29, no. 15 (2011)
105. Momenimovahed Z, Ghoncheh M, Pakzad R, Hasanpour H, Salehiniya H. Incidence and mortality of uterine cancer and relationship with Human Development Index in the world. *Cukurova Medical Journal*. 2017;42(2):233–240.
106. Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. *J Clin Endocrinol Metab* (2009) 94:1761–7. [10.1210/jc.2008-1741](https://doi.org/10.1210/jc.2008-1741)
107. Moore HC, Unger JM, Phillips KA et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med* 2015; 372: 923–932.
108. Murphy CE, Carder PJ, Lansdown MR, Speirs V. Steroid hormone receptor expression in male breast cancer. *Eur J of Surg Oncol*. 2006;32:44–7
109. Murphy, C. C. et al. (2012) ‘Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review’, *Breast Cancer Research and Treatment*, 134(2), pp. 459–478. doi: 10.1007/s10549-012-2114-5.
110. N. Krishnamurthy, R. Kurzrock Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors *Cancer Treat Rev*, 62 (2018), pp. 50-60
111. Navarro VM, Castellano JM, McConkey SM, Pineda R, Ruiz-Pino F, Pinilla L, Clifton DK, Tena-Sempere M, Steiner RA. Interactions between kisspeptin

- and neurokinin B in the control of GnRH secretion in the female rat. *Am J Physiol Endocrinol Metab.* 2011;300:E202–210.
112. Niaz MI, Farooq O, Tirmazi FH. Efficacy of triple assessment in diagnosis of malignant breast lump. *Professional Med J Oct* 2012;19(5): 620-624.
113. Nichol, A.M., Chan, E.K., Lucas, S. et al. The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. *Int J Radiat Oncol Biol Phys.* 2017; 98: 829–839
114. Octavian dkk. “Organoids as Reliable Breast Cancer Study Models: An Update.” *International Journal of Oncology Research*, vol. 1, no. 2, 2018.
115. P. Wee, Z. Wang Epidermal growth factor receptor cell proliferation signaling pathways *Cancers (Basel)*, 9 (5) (2017)
116. Pagni, P., Spunticchia, F., Barberi, S., Caprio, G., & Paglicci, C. (2014). Use of Core Needle Biopsy rather than Fine-Needle Aspiration Cytology in the Diagnostic Approach of Breast Cancer. *Case Reports in Oncology*, 7(2), 452–458.
117. Pan H, Gray R, Braybrooke J, et al; EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med.* 2017;377(19):1836-1846. doi:10.1056/NEJMoa1701830
118. Park, W.-C. (2016). Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer. *Journal of Breast Cancer*, 19(4), 341.



119. Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. *J Magn Reson Imaging*. 2010;31:562–70.
120. Patricio, B.-P., & Sergio, B.-G. (2019). Normal Menstrual Cycle. *Menstrual Cycle*. doi:10.5772/intechopen.79876
121. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*. 2015;24(Suppl 2):S26–S35.
122. Prat A., Pineda E., Adamo B., et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*. 2015;24:S26–S35.
123. Q. Liu, M.V. Kulak, N. Borchering, et al. A novel HER2 gene body enhancer contributes to HER2 expression *Oncogene*, 37 (5) (2018), pp. 687-694
124. R.J. Huebner, A.J. Ewald Cellular foundations of mammary tubulogenesis *Semin Cell Dev Biol*, 31 (2014), pp. 124-131
125. R.J. Santen, W. Yue, J.P. Wang, Estrogen metabolites and breast cancer, *Steroids* 99 (2015) 61–66.
126. R.S. Finn, A. Aleshin, D.J. Slamon Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers *Breast Cancer Res*, 18 (1) (2016), p. 17
127. Rohilla M and TMuthyala T. Current Concepts in Role of Bilateral Salpingo-Oophorectomy in Non-Hereditary Metastatic Carcinoma of Breast: Review Article. *Journal of Gynecological Oncology* 2019;2 (1):1008

128. Rosato V, Bosetti C, Negri E. et al. Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status. *Eur J Cancer Prev.* 2014;23:412–417.
129. S. Thongprakaisang, A. Thiantanawat, N. Rangkadilok, T. Suriyo, J.Satayavivad, Glyphosate induces human breast cancer cells growth via estrogen receptors, *Food Chem. Toxicol.* 59 (2013) 129–136.
130. Sadler, T. W. Breast embryology in *Langmans Medical Embryology 14th .USA : Wolters Kluwer, 2019.*
131. Samavat, H., & Kurzer, M. S. (2015). Estrogen metabolism and breast cancer. *Cancer Letters*, 356(2), 231–243. doi:10.1016/j.canlet.2014.04.018
132. Schubert A, Hawighorst T, Emons G, Grundker C. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. *Breast Cancer Res Treat* (2011) 130:783–90.10.1007/s10549-011-1358-9
133. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. *Arch Pathol Lab Med.* 2014;138:1048–1052
134. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al, on behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 26 (Supplement 5): v8–v30, 2015

135. Shaheen R, Schimmelpenninck CA, Stoddart L, Raymond H, Slanetz PJ. Spectrum of diseases presenting as architectural distortion on mammography: multimodality radiologic imaging with pathologic correlation. *Semin Ultrasound CT MR*. 2011;32:351–62.
136. Sherwood, Lauralee. *Human Physiology: from Cells to Systems*. 9th Edition. USA : Cengage Learning, 2016.
137. Shiffman, M. A. (2014). Arterial Blood Supply of the Breast. *Aesthetic Surgery of the Breast*, 43–44. doi:10.1007/978-3-662-43407-9\_5
138. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin*. 2013;63:11–30
139. Siegel RL, Miller KD, and Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017; 67: 7-30
140. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017;67:7–30
141. Singh G. Oophorectomy in breast cancer-controversies and current status. *Indian J Surg* 2012;74:210-2
142. Sinn, H.-P., & Kreipe, H. (2013). A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. *Breast Care*, 8(2), 149–154. doi:10.1159/000350774
143. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. *Hum Reprod Update*. 2014;20:485–500.

144. Soroush A, Farshchian N, Komasi S. et al. The Role of Oral Contraceptive Pills on Increased Risk of Breast Cancer in Iranian Populations: A Meta-analysis. *Journal of cancer prevention*. 2016;21:294–301.
145. Stewart BW, and Wild CP. *World Cancer Report 2014*. Geneva, Switzerland: WHO Press; 2014
146. Suh KJ, Kim SH, Lee KH, Kim TY, Kim YJ, Han SW, et al. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor? Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. *Cancer Res Treat*. 2017;49(4):1153-63.
147. Sultania, M., Kataria, K., Srivastava, A., Misra, M. C., Parshad, R., Dhar, A., ... Thulkar, S. (2016). Validation of Different Techniques in Physical Examination of Breast. *Indian Journal of Surgery*, 79(3), 219–225
148. Sun, Y.-S., (2017). Risk Factors and Preventions of Breast Cancer. *International Journal of Biological Sciences*, 13(11), 1387–1397. doi:10.7150/ijbs.21635
149. Tan MP, Sitoh NY, Sim AS. The value of intraoperative frozen section analysis for margin status in breast conservation surgery in a nontertiary institution. *Int J Breast Cancer* 2014; 2014: 715404.
150. Thomas, M. P., & Potter, B. V. L. (2013). The structural biology of oestrogen metabolism. *The Journal of Steroid Biochemistry and Molecular Biology*, 137, 27–49

151. Tutt A, Ellis P, Kilburn L, et al. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. In: San Antonio Breast Cancer Symposium; December 9-13, 2014. Abstract S3-01
152. Valente SA, Levine GM, Silverstein MJ, Rayhanabad JA, Weng-Grumley JG, Ji L, et al. Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. *Ann Surg Oncol*. 2012;19:1825–1830.
153. Valentini A, Lubinski J, Byrski T, et al; Hereditary Breast Cancer Clinical Study Group. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. *Breast Cancer Res Treat*. 2013;142(1):177-185.
154. Verheuel NC, van den Hoven I, Ooms HW, Voogd AC, Roumen RM. The role of ultrasound-guided lymph node biopsy in axillary staging of invasive breast cancer in the post-ACOSOG Z0011 trial era. *Ann Surg Oncol*. 2015;22:409–415.
155. von Minckwitz G, Loibl S, Schneeweiss A, et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). In: San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. Abstract S2-04.

156. W. Yue, J.D. Yager, J.P. Wang, E.R. Jupe, R.J. Santen, Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis, *Steroids* 78 (2013) 161–170.
157. Wamalwa, A O, Stasch, T, Nangole, F W, & Khainga, S O. (2017). Surgical anatomy of reduction mammoplasty: a historical perspective and current concepts. *South African Journal of Surgery*, 55(1), 22-28.
158. Wang J, Xu B, Yuan P, Ma F, Li Q, Zhang P, et al. Phase II trial of goserelin and exemestane combination therapy in premenopausal women with locally advanced or metastatic breast cancer. *Medicine (Baltimore)*. 2015;94:e1006.
159. Wang M., Hou L., Chen M., et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. *Sci. Rep.* 2017;7:44673.
160. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. *J Pathol.* 2010;220(2):263–280.
161. Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010). Histological types of breast cancer: How special are they? *Molecular Oncology*, 4(3), 192–208.
162. Wineski, Lawrence E., and Richard S. Snell. *Snells Clinical Anatomy by Regions*. Wolters Kluwer, 2019.
163. Winters, S., Martin, C., Murphy, D. & Shokar, N. K. Breast cancer epidemiology, prevention, and screening. *Prog. Mol. Biol. Transl Sci.* 151, 1–32 (2017).

164. Wolff A, Hammond M, Hicks D, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol.* 2013;31(31):3997–4013
165. Xiao Y-L, Wang K, Liu Q, Li J, Zhang X, Li H-Y, Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: a meta-analysis and systematic review, *Clinical Breast Cancer* (2018).
166. Y. Yang, M. Leonard, Y. Zhang, et al. HER2-Driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1 *Cancer Res*, 78 (2) (2018), pp. 422-435
167. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. *J Clin Oncol.* 2011; 29:4654–4661
168. Yi-Sheng Sun, Zhao Zhao, Zhang-Nv Yang, et al. Risk Factors and Preventions of Breast Cancer. *Int. J. Biol. Sci.* 2017, Vol. 13
169. Zagouri F, N Sergentanis, V Koutoulidis, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. *British Journal of Cancer* volume 108, pages2259–2263 (2013)

170. Zhen Huang, Qixing Tan, Qinghong Qin, Qinguo Mo, and Changyuan Wei.  
Impact of Primary Site Surgery on Survival of Patients with de novo Stage IV  
Breast Cancer. *Cancer Manag Res.* 2021; 13: 319–327.





KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN KESEHATAN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,M.Med.,PhD., SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

### **REKOMENDASI PERSETUJUAN ETIK**

Nomor : 739/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 24 Nopember 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21110695	No Sponsor Protokol	
Peneliti Utama	<b>dr. Dwi Ris Adriyanto</b>	Sponsor	
Judul Peneliti	Perbandingan Prosedur Ooforektomi dengan Pemberian Gonadotropin Releasing Hormone (GnRH) Analog Sebagai Terapi Pada Kanker Payudara.		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>15 Nopember 2021</b>
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin, RS Dr. Wahidin Sudirohusodo dan RS Jejjaring di Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>24 Nopember 2021</b> sampai <b>24 Nopember 2022</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH RSUH dan RSWS	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH RSUH dan RSWS	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET, DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN

UPT PUSAT BAHASA

JL. PERINTIS KEMERDEKAAN KM. 10 KAMPUS TAMALANREA  
MAKASSAR 90245 INDONESIA

Email : [unhaspusatbahasa@gmail.com](mailto:unhaspusatbahasa@gmail.com) HP 081344431789

## SURAT KETERANGAN ABSTRAK

Yang bertanda tangan di bawah ini menerangkan bahwa :

Nama : dr Dwi Ris Andriyanto  
 No. Pokok : C 104216110  
 Program Studi : Ilmu BEDAH  
 Judul Tesis/Disertasi : Perbandingan Dexam Preo survival (DFS) pemberian Analog Gonadotropin - Releasing Hormone (GnRH) dan Salpingo-oophorectomi bilateral pada pasien Kanker payudara stadium lanjut lokal tipe Hormonal  
 Judul Jurnal :  
 .....  
 .....  
 .....

Menyatakan bahwa naskah abstrak yang disusun oleh mahasiswa tersebut di atas telah diedit dan diterjemahkan di Pusat Bahasa Unhas.

Makassar, ..... 8. Juli 2022

Mengetahui,  
Kepala Pusat Bahasa,



Dra. Herawaty, M.Hum., M.A., Ph.D. ↓  
NIP. 19630103 198803 2 003







KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEDOKTERAN

Jl. Perintis Kemerdekaan Kampus Tamalanrea Km. 10 Makassar 90245 Telp. (0411) 5077912, 586010 (0411) 586200  
Fax. 586010 Email : [fkunhas@med.unhas.ac.id](mailto:fkunhas@med.unhas.ac.id)

**SURAT KEPUTUSAN**  
**DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN**  
**No.3168/UN4.6.1/KEP/2022**  
**TENTANG**

**PENGANGKATAN PEMBIMBING SEMINAR USUL, HASIL DAN UJIAN AKHIR BAGI MAHASISWA**  
**Sdr. : dr. DWI RIS ANDRIYANTO NOMOR POKOK : C104216110**  
**PROGRAM PENDIDIKAN DOKTER SPESIALIS ILMU BEDAH**  
**FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN**

**DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN**

- Membaca : Surat Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Unhas Nomor : 10660/UN4.6.8/PT.01.06/2022 tanggal 17 Mei 2022 perihal SK Pembimbing Karya Akhir bagi Sdr. **dr. Dwi Ris Andriyanto** dengan Judul Penelitian: **"Perbandingan Disease Free Survival (Dfs) Pemberian GnRH Analog dan Salpingo-Ooforektomi Bilateral pada Pasien Kanker Payudara Stadium Lanjut Lokal Tipe Luminal"**
- Menimbang : a. Bahwa dalam rangka pelaksanaan Bimbingan Karya Akhir bagi Sdr. **dr. Dwi Ris Andriyanto** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin, dipandang perlu mengangkat Tim Pembimbing Karya Akhir  
b. Bahwa untuk keperluan huruf (a) di atas, maka dipandang perlu menerbitkan surat Keputusannya.
- Mengingat : 1. Keputusan Rektor Unhas No. 977/J04/O/2005  
2. Keputusan Rektor Unhas No. 2283/H4/P/2007  
3. Keputusan Rektor Unhas No. 1784/H4.2/K/2010  
4. Keputusan Rektor Unhas No. 1282/H4.2/K/2011  
5. Keputusan Rektor Unhas No. 8650/UN4.2/KU.10/2012  
6. Keputusan Rektor Unhas No. 8765/UN4.2/KU.10/2013

**MEMUTUSKAN**

- Menetapkan :  
Pertama : Membentuk Tim Pembimbing Karya Akhir bagi Sdr. **dr. Dwi Ris Andriyanto** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin dengan susunan sebagai berikut :  
1. Dr. dr. Prihantono, Sp.B(K)Onk, M.Kes Pembimbing Utama  
2. dr. Joko Hendarto, M.Biomed, Ph.D Pembimbing Pendamping
- Kedua : Segala biaya yang timbul sehubungan dengan Surat Keputusan ini dibebankan pada Anggaran DPA PTN Badan Hukum Tahun 2022 alokasi Fakultas Kedokteran Universitas Hasanuddin.
- Ketiga : Surat Keputusan ini berlaku terhitung mulai tanggal ditetapkannya, dengan ketentuan apabila dikemudian hari ternyata terdapat kesalahan atau kekeliruan didalamnya akan diadakan perbaikan sebagaimana mestinya.

Ditetapkan di : Makassar  
Pada tanggal : 18 Mei 2022

**a.n Dekan**  
**Wakil Dekan Bid. Akademik, Riset dan Inovasi**



Tembusan :

1. Ketua Program Studi **Ilmu Bedah**
2. Masing-masing yang bersangkutan untuk dilaksanakan
3. **dr. Dwi Ris Andriyanto**



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEDOKTERAN

Jl. Perintis Kemerdekaan Kampus Tamalanrea Km. 10 Makassar 90245 Telp. (0411) 5077912, 586010 (0411) 586200  
Fax. 586010 Email : fkuhas@med.unhas.ac.id

**SURAT KEPUTUSAN**  
**DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN**  
**No.3169/UN4.6.1/KEP/2022**

**TENTANG**

**PENGANGKATAN PENILAI SEMINAR USUL, HASIL DAN UJIAN AKHIR BAGI MAHASISWA**  
**Sdr. : dr. DWI RIS ANDRIYANTO NOMOR POKOK : C104216110**  
**PROGRAM PENDIDIKAN DOKTER SPESIALIS ILMU BEDAH**  
**FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN**

**DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN**

- Membaca : Surat Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Unhas Nomor : 10659/UN4.6.8/PT.01.06/2022 tanggal 17 Mei 2022 tentang Penilai Seminar Usul dan Hasil Penelitian bagi **dr. Dwi Ris Andriyanto** dengan Judul Penelitian: **"Perbandingan Disease Free Survival (Dfs) Pemberian GnRh Analog dan Salpingo-Ooforektomi Bilateral pada Pasien Kanker Payudara Stadium Lanjut Lokal Tipe Luminal"**
- Menimbang: a. Bahwa dalam rangka pelaksanaan Seminar Usul dan Hasil Penelitian Sdr. **dr. Dwi Ris Andriyanto** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin, dipandang perlu mengangkat Tim Penilai.  
b. Bahwa untuk keperluan huruf (a) di atas, maka dipandang perlu menerbitkan surat keputusannya.
- Mengingat : 1. Keputusan Rektor Unhas No. 1067/J04/P/2003  
2. Keputusan Rektor Unhas No. 977/J04/O/2005  
3. Keputusan Rektor Unhas No. 2283/H4/P/2007  
4. Keputusan Rektor Unhas No. 1784/H4.2/K/2010  
5. Keputusan Rektor Unhas No. 1282/H4.2/K/2011  
6. Keputusan Rektor Unhas No. 8650/UN4.2/KU.10/2012  
7. Keputusan Rektor Unhas No. 8765/UN4.2/KU.10/2013

**MEMUTUSKAN**

- Menetapkan :  
Pertama : Membentuk Tim Penilai Seminar Usul dan Hasil Penelitian bagi Sdr. **dr. Dwi Ris Andriyanto** Nomor Pokok : **C104216110** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin dengan susunan sebagai berikut:
- |  |                    |
|--|--------------------|
| 1. Dr. dr. Prihantono, Sp.B(K)Onk, M.Kes | Penguji Utama      |
| 2. dr. Joko Hendarto, M.Biomed, Ph.D     | Penguji Pendamping |
| 3. dr. M. Ihwan Kusuma, Sp.B-KBD         | Penguji Pendamping |
| 4. dr. Salman Ardy Syamsu, Sp.B(K)Onk    | Penguji Pendamping |
- Kedua : Segala biaya yang timbul sehubungan dengan Surat Keputusan ini dibebankan pada Anggaran DPA PTN Badan Hukum Tahun 2022 alokasi Fakultas Kedokteran Universitas Hasanuddin.
- Ketiga : Surat Keputusan ini berlaku terhitung mulai tanggal ditetapkannya, dengan ketentuan apabila dikemudian hari ternyata terdapat kesalahan atau kekeliruan di dalamnya akan diadakan perbaikan sebagaimana mestinya.

Ditetapkan di : Makassar  
Pada tanggal : 18 Mei 2022

**a.n Dekan**  
**Wakil Dekan Bid. Akademik, Riset dan Inovasi**

**Dr. dr. Irfan Idris, M.Kes**  
**NIP 19671103 199802 1 00415**



Tembusan :

1. Ketua Program Studi **Ilmu Bedah**
2. Masing-masing yang bersangkutan untuk dilaksanakan
3. **dr. Dwi Ris Andriyanto**